MX2023002539A - Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv). - Google Patents
Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv).Info
- Publication number
- MX2023002539A MX2023002539A MX2023002539A MX2023002539A MX2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A
- Authority
- MX
- Mexico
- Prior art keywords
- conditions
- mediated diseases
- methods
- pde
- treating
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La descripción proporciona métodos y composiciones para el tratamiento de enfermedades o afecciones mediadas por PDE IV, incluidas las enfermedades o afecciones inflamatorias, con el uso de un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076774P | 2020-09-10 | 2020-09-10 | |
| PCT/US2021/049870 WO2022056265A1 (en) | 2020-09-10 | 2021-09-10 | Methods of treating pde iv-mediated diseases or conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002539A true MX2023002539A (es) | 2023-03-14 |
Family
ID=78080507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002539A MX2023002539A (es) | 2020-09-10 | 2021-09-10 | Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv). |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230364100A1 (es) |
| EP (1) | EP4210674A1 (es) |
| JP (1) | JP2023541261A (es) |
| KR (1) | KR20230066350A (es) |
| CN (1) | CN116507336A (es) |
| AU (1) | AU2021338837A1 (es) |
| BR (1) | BR112023004214A2 (es) |
| CA (1) | CA3191177A1 (es) |
| CL (1) | CL2023000648A1 (es) |
| IL (1) | IL300628A (es) |
| MX (1) | MX2023002539A (es) |
| WO (1) | WO2022056265A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060089375A1 (en) | 2002-09-16 | 2006-04-27 | Allen David G | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
| JP6938510B2 (ja) | 2015-12-24 | 2021-09-22 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｃｆｔｒ制御因子及びこの使用方法 |
| AU2018321926B2 (en) * | 2017-08-24 | 2023-09-21 | The Regents Of The University Of California | Ocular pharmaceutical compositions |
-
2021
- 2021-09-10 EP EP21787173.0A patent/EP4210674A1/en active Pending
- 2021-09-10 CA CA3191177A patent/CA3191177A1/en active Pending
- 2021-09-10 KR KR1020237008089A patent/KR20230066350A/ko unknown
- 2021-09-10 CN CN202180062221.XA patent/CN116507336A/zh active Pending
- 2021-09-10 JP JP2023515808A patent/JP2023541261A/ja active Pending
- 2021-09-10 WO PCT/US2021/049870 patent/WO2022056265A1/en active Application Filing
- 2021-09-10 BR BR112023004214A patent/BR112023004214A2/pt unknown
- 2021-09-10 IL IL300628A patent/IL300628A/en unknown
- 2021-09-10 AU AU2021338837A patent/AU2021338837A1/en active Pending
- 2021-09-10 MX MX2023002539A patent/MX2023002539A/es unknown
- 2021-09-10 US US18/044,805 patent/US20230364100A1/en active Pending
-
2023
- 2023-03-07 CL CL2023000648A patent/CL2023000648A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023004214A2 (pt) | 2023-04-11 |
| US20230364100A1 (en) | 2023-11-16 |
| EP4210674A1 (en) | 2023-07-19 |
| CA3191177A1 (en) | 2022-03-17 |
| JP2023541261A (ja) | 2023-09-29 |
| CL2023000648A1 (es) | 2023-10-13 |
| KR20230066350A (ko) | 2023-05-15 |
| IL300628A (en) | 2023-04-01 |
| CN116507336A (zh) | 2023-07-28 |
| WO2022056265A1 (en) | 2022-03-17 |
| AU2021338837A1 (en) | 2023-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001689A (es) | Inhibidores de bcl-2. | |
| MX2023010806A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2022000244A (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas. | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2021012105A (es) | Compuestos de pirrol. | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). | |
| ZA202300912B (en) | Tyk-2 inhibitor | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| PH12019502652A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| MX2022002446A (es) | Compuestos de pirrolopirimidina inhibidores de perk. | |
| JOP20210319A1 (ar) | مركبات بيروليدين |